Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 12(1): e0168395, 2017.
Article in English | MEDLINE | ID: mdl-28045991

ABSTRACT

Low-energy X-rays induce Auger cascades by photoelectric absorption in iodine present in the DNA of cells labeled with 5-iodo-2'-deoxyuridine (IUdR). This photoactivation therapy results in enhanced cellular sensitivity to radiation which reaches its maximum with 50 keV photons. Synchrotron core facilities are the only way to generate such monochromatic beams. However, these structures are not adapted for the routine treatment of patients. In this study, we generated two beams emitting photon energy means of 42 and 50 keV respectively, from a conventional 225 kV X-ray source. Viability assays performed after pre-exposure to 10 µM of IUdR for 48h suggest that complex lethal damage is generated after low energy photons irradiation compared to 137Cs irradiation (662KeV). To further decipher the molecular mechanisms leading to IUdR-mediated radiosensitization, we analyzed the content of DNA damage-induced foci in two glioblastoma cell lines and showed that the decrease in survival under these conditions was correlated with an increase in the content of DNA damage-induced foci in cell lines. Moreover, the follow-up of repair kinetics of the induced double-strand breaks showed the maximum delay in cells labeled with IUdR and exposed to X-ray irradiation. Thus, there appears to be a direct relationship between the reduction of radiation survival parameters and the production of DNA damage with impaired repair of these breaks. These results further support the clinical potential use of a halogenated pyrimidine analog combined with low-energy X-ray therapy.


Subject(s)
Cell Survival/drug effects , DNA Damage/drug effects , Dose-Response Relationship, Radiation , Idoxuridine/pharmacology , Radiation Tolerance/drug effects , Radiation-Sensitizing Agents/pharmacology , Animals , Cell Line, Tumor , Cesium Radioisotopes , Humans , Kinetics , Photons , Rats , Synchrotrons , Tumor Suppressor p53-Binding Protein 1/metabolism , X-Rays
2.
Curr Gene Ther ; 13(2): 73-92, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23320476

ABSTRACT

The unlimited proliferation capacity of embryonic stem cells (ESCs) combined with their pluripotent differentiation potential in various lineages raised great interest in both the scientific community and the public at large with hope for future prospects of regenerative medicine. However, since ESCs are derived from human embryos, their use is associated with significant ethical issues preventing broad studies and therapeutic applications. To get around this bottleneck, Takahashi and Yamanaka have recently achieved the conversion of adult somatic cells into ES-like cells via the forced expression of four transcription factors: Oct3/4, Sox2, Klf4 and c-Myc. This first demonstration attracted public attention and opened a new field of stem cells research with both cognitive - such as disease modeling - and therapeutic prospects. This pioneer work just received the 2012 Nobel Prize in Physiology or Medicine. Many methods have been reported since 2006, for the generation of induced pluripotent stem (iPS) cells. Most strategies currently under use are based on gene delivery via gamma-retroviral or lentiviral vectors; some experiments have also been successful using plasmids or transposons- based systems and few with adenovirus. However, most experiments involve integration in the host cell genome with an identified risk for insertional mutagenesis and oncogenic transformation. To circumvent such risks which are deemed incompatible with therapeutic prospects, significant progress has been made with transgene-free reprogramming methods based on e.g.: sendai virus or direct mRNA or protein delivery to achieve conversion of adult cells into iPS. In this review we aim to cover current knowledge relating to both delivery systems and combinations of inducing factors including chemicals which are used to generate human iPS cells. Finally, genetic instability resulting from the reprogramming process is also being considered as a safety bottleneck for future clinical translation and stem cell-therapy prospects based on iPS.


Subject(s)
Cell Differentiation , Cellular Reprogramming , Induced Pluripotent Stem Cells/cytology , Regenerative Medicine , Adult , Cell- and Tissue-Based Therapy , Embryonic Stem Cells/cytology , Gene Expression Regulation, Developmental , Genetic Therapy , Humans , Induced Pluripotent Stem Cells/transplantation , Kruppel-Like Factor 4 , Nobel Prize
3.
J Biol Chem ; 285(40): 30767-78, 2010 Oct 01.
Article in English | MEDLINE | ID: mdl-20630870

ABSTRACT

Efficiency of translation termination relies on the specific recognition of the three stop codons by the eukaryotic translation termination factor eRF1. To date only a few proteins are known to be involved in translation termination in eukaryotes. Saccharomyces cerevisiae Tpa1, a largely conserved but uncharacterized protein, has been described to associate with a messenger ribonucleoprotein complex located at the 3' end of mRNAs that contains at least eRF1, eRF3, and Pab1. Deletion of the TPA1 gene results in a decrease of translation termination efficacy and an increase in mRNAs half-lives and longer mRNA poly(A) tails. In parallel, Schizosaccharomyces pombe Ofd1, a Tpa1 ortholog, and its partner Nro1 have been implicated in the regulation of the stability of a transcription factor that regulates genes essential for the cell response to hypoxia. To gain insight into Tpa1/Ofd1 function, we have solved the crystal structure of S. cerevisiae Tpa1 protein. This protein is composed of two equivalent domains with the double-stranded ß-helix fold. The N-terminal domain displays a highly conserved active site with strong similarities with prolyl-4-hydroxylases. Further functional studies show that the integrity of Tpa1 active site as well as the presence of Yor051c/Ett1 (the S. cerevisiae Nro1 ortholog) are essential for correct translation termination. In parallel, we show that Tpa1 represses the expression of genes regulated by Hap1, a transcription factor involved in the response to levels of heme and oxygen. Altogether, our results support that Tpa1 is a putative enzyme acting as an oxygen sensor and influencing several distinct regulatory pathways.


Subject(s)
Carrier Proteins/chemistry , Peptide Chain Termination, Translational/physiology , Procollagen-Proline Dioxygenase/chemistry , Protein Folding , Saccharomyces cerevisiae Proteins/chemistry , Saccharomyces cerevisiae/enzymology , Transcription, Genetic/physiology , Carrier Proteins/genetics , Carrier Proteins/metabolism , Catalytic Domain , Crystallography, X-Ray , DNA-Binding Proteins/chemistry , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation, Fungal/physiology , Heme/chemistry , Heme/genetics , Heme/metabolism , Oxygen/chemistry , Oxygen/metabolism , Procollagen-Proline Dioxygenase/genetics , Procollagen-Proline Dioxygenase/metabolism , Protein Structure, Secondary , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae Proteins/genetics , Saccharomyces cerevisiae Proteins/metabolism , Structure-Activity Relationship , Transcription Factors/chemistry , Transcription Factors/genetics , Transcription Factors/metabolism
4.
Mol Cancer Res ; 8(3): 385-94, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20215422

ABSTRACT

Little is known about the functional interaction between the Bloom's syndrome protein (BLM) and the recombinase RAD51 within cells. Using RNA interference technology, we provide the first demonstration that RAD51 acts upstream from BLM to prevent anaphase bridge formation. RAD51 downregulation was associated with an increase in the frequency of BLM-positive anaphase bridges, but not of BLM-associated ultrafine bridges. Time-lapse live microscopy analysis of anaphase bridge cells revealed that BLM promoted cell survival in the absence of Rad51. Our results directly implicate BLM in limiting the lethality associated with RAD51 deficiency through the processing of anaphase bridges resulting from the RAD51 defect. These findings provide insight into the molecular basis of some cancers possibly associated with variants of the RAD51 gene family.


Subject(s)
Neoplasms/genetics , Rad51 Recombinase/genetics , RecQ Helicases/genetics , Anaphase/genetics , Cell Death/genetics , Cell Survival/genetics , Down-Regulation/genetics , Gene Expression Regulation, Neoplastic/genetics , HeLa Cells , Humans , Neoplasms/metabolism , RNA Interference/physiology , RecQ Helicases/metabolism , Sister Chromatid Exchange/genetics
5.
EMBO J ; 27(10): 1513-24, 2008 May 21.
Article in English | MEDLINE | ID: mdl-18418389

ABSTRACT

Topoisomerase (Topo) IIIalpha associates with BLM helicase, which is proposed to be important in the alternative lengthening of telomeres (ALT) pathway that allows telomere recombination in the absence of telomerase. Here, we show that human Topo IIIalpha colocalizes with telomeric proteins at ALT-associated promyelocytic bodies from ALT cells. In these cells, Topo IIIalpha immunoprecipitated with telomere binding protein (TRF) 2 and BLM and was shown to be associated with telomeric DNA by chromatin immunoprecipitation, suggesting that these proteins form a complex at telomere sequences. Topo IIIalpha depletion by small interfering RNA reduced ALT cell survival, but did not affect telomerase-positive cell lines. Moreover, repression of Topo IIIalpha expression in ALT cells reduced the levels of TRF2 and BLM proteins, provoked a strong increase in the formation of anaphase bridges, induced the degradation of the G-overhang signal, and resulted in the appearance of DNA damage at telomeres. In contrast, telomere maintenance and TRF2 levels were unaffected in telomerase-positive cells. We conclude that Topo IIIalpha is an important telomere-associated factor, essential for telomere maintenance and chromosome stability in ALT cells, and speculate on its potential mechanistic function.


Subject(s)
Chromosomal Instability , DNA Topoisomerases, Type I/metabolism , Telomere/metabolism , Telomere/ultrastructure , Adenosine Triphosphatases/analysis , Adenosine Triphosphatases/metabolism , Anaphase , Cell Line , Cell Proliferation/drug effects , Chromatin Immunoprecipitation , Chromosomal Instability/genetics , DNA Helicases/analysis , DNA Helicases/metabolism , DNA Topoisomerases, Type I/analysis , DNA Topoisomerases, Type I/genetics , Humans , Neoplasm Proteins/analysis , Neoplasm Proteins/metabolism , Nuclear Proteins/analysis , Nuclear Proteins/metabolism , Promyelocytic Leukemia Protein , Protein Subunits/analysis , Protein Subunits/metabolism , RNA, Small Interfering/genetics , RNA, Small Interfering/pharmacology , RecQ Helicases , Shelterin Complex , Telomere-Binding Proteins/analysis , Telomere-Binding Proteins/metabolism , Telomeric Repeat Binding Protein 2/analysis , Telomeric Repeat Binding Protein 2/metabolism , Transcription Factors/analysis , Transcription Factors/metabolism , Tumor Suppressor Proteins/analysis , Tumor Suppressor Proteins/metabolism
6.
Cell Cycle ; 5(15): 1681-6, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16880735

ABSTRACT

Bloom syndrome (BS) is a rare human autosomal recessive disorder characterized by marked genetic instability associated with greatly increased predisposition to a wide range of cancers affecting the general population. BS arises through mutations in both copies of the BLM gene which encodes a 3'-5' DNA helicase identified as a member of the RecQ family. Several studies support a major role for BLM in the cellular response to DNA damage and stalled replication forks. However, the specific function(s) of BLM remain(s) unclear. The BLM protein is strongly expressed and phosphorylated during mitosis, but very little information is available about the origin and the significance of this phosphorylation. We show here that ATM kinase provides only a limited contribution to the mitotic phosphorylation of BLM. We also demonstrate that BLM is directly phosphorylated at multiple sites in vitro by the mitotic cdc2 kinase, and identify two new sites of mitotic BLM phosphorylation: Ser-714 and Thr-766. Our results identify BLM helicase as a new substrate for cdc2, which may have potential physiological implications for the role of BLM in mitosis.


Subject(s)
Adenosine Triphosphatases/metabolism , CDC2 Protein Kinase/metabolism , DNA Helicases/metabolism , Mitosis , Adenosine Triphosphatases/chemistry , Ataxia Telangiectasia Mutated Proteins , Cell Cycle Proteins/metabolism , DNA Helicases/chemistry , DNA-Binding Proteins/metabolism , HeLa Cells , Humans , Models, Genetic , Phosphorylation , Phosphoserine/metabolism , Phosphothreonine/metabolism , Protein Serine-Threonine Kinases/metabolism , Protein Structure, Tertiary , RecQ Helicases , Tumor Cells, Cultured , Tumor Suppressor Proteins/metabolism
7.
Cancer Res ; 64(24): 8954-9, 2004 Dec 15.
Article in English | MEDLINE | ID: mdl-15604258

ABSTRACT

Cdc2 kinase is inactivated when DNA damage occurs during the spindle assembly checkpoint. Here, we show that the level of mitotic Bloom syndrome protein phosphorylation reflects the level of cdc2 activity. A complete inactivation of cdc2 by either introduction of DNA double-strand breaks or roscovitine treatment prevents exit from mitosis. Thus, mitotic cdc2 inactivation plays a major role in the establishment of the mitotic DNA damage checkpoint. In response to mitotic cdc2 inactivation, the M/G(1) transition is delayed after releasing the drug block in nonmalignant cells, whereas tumor cells exit mitosis without dividing and rereplicate their DNA, which results in mitotic catastrophe. This opens the way for new chemotherapeutic strategies.


Subject(s)
CDC2 Protein Kinase/metabolism , DNA Damage/physiology , Mitosis/physiology , Adenosine Triphosphatases/metabolism , CDC2 Protein Kinase/antagonists & inhibitors , Cell Division/physiology , Chloroquine/pharmacology , DNA/drug effects , DNA/metabolism , DNA Helicases/metabolism , Enzyme Activation , G1 Phase/physiology , HeLa Cells , Humans , Hydroxamic Acids/pharmacology , Mitosis/drug effects , Mitosis/genetics , Phosphorylation/drug effects , Purines/pharmacology , RecQ Helicases , Roscovitine , Subcellular Fractions/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...